Boehringer Ingelheim
Boehringer Ingelheim, a leading global pharmaceutical company, is headquartered in Ingelheim am Rhein, Germany. Founded in 1885, the company has established a strong presence in the healthcare industry, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a commitment to innovation, Boehringer Ingelheim is renowned for its core products, including treatments for respiratory diseases, cardiovascular conditions, and diabetes management. The company’s dedication to research and development has led to significant milestones, positioning it among the top pharmaceutical firms worldwide. Notable achievements include a robust pipeline of novel therapies and a strong market presence in Europe, North America, and Asia. Boehringer Ingelheim continues to enhance its reputation through its unique approach to healthcare solutions, prioritising patient needs and sustainable practices.
DitchCarbon Score
How does Boehringer Ingelheim's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim's score of 32 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim's reported carbon emissions
In 2023, Boehringer Ingelheim reported carbon emissions of approximately 295,000,000 kg CO2e for Scope 1 and about 66,000,000 kg CO2e for Scope 2. The company has not disclosed any Scope 3 emissions for this year. Over the years, Boehringer Ingelheim has made significant strides in reducing its carbon footprint. For instance, in 2022, the company recorded emissions of about 280,000,000 kg CO2e for Scope 1 and approximately 71,000,000 kg CO2e for Scope 2, indicating a commitment to lowering its environmental impact. Boehringer Ingelheim has implemented various initiatives aimed at reducing its carbon emissions, although specific reduction targets have not been disclosed. The company is actively working towards sustainability and has made commitments to improve its climate performance, as evidenced by its ongoing efforts to monitor and report emissions data. The GHG Emissions Index, which normalises emissions to net sales, shows a decreasing trend, with a value of 0.48 in 2023 compared to 0.49 in 2022. Overall, Boehringer Ingelheim's focus on reducing its carbon emissions reflects its commitment to environmental sustainability and climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 289,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 273,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 3,801,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boehringer Ingelheim is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
